1 link tagged with all of: fda + healthcare + clinical-trials + biotechnology
Click any tag below to further narrow down your results
Links
The FDA plans to reduce the number of required pivotal trials in Phase 3 clinical studies from two to one, aiming to streamline drug development. While this may benefit smaller biotech companies, the impact will vary by disease, as some conditions may still necessitate more trials to ensure safety and efficacy.